Valeur202020212022202320242025Total du passif78.63 M96.27 M126.17 M53.6 M44.69 M50.21 MTotal des capitaux propres461.14 M399.67 M222.36 M117.35 M68.5 M24.1 MTotal du passif et des capitaux propres539.77 M495.94 M348.53 M170.95 M113.2 M74.31 MDette totale———16.77 M——Dette nette———-128.53 M——
Inovio Pharmaceuticals, Inc. - Common Stock
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.